Amgen annual dividends paid
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Dividends Paid Growth & History (AMGN)
Amgen paid $5.12B in dividends during fiscal 2025.
View full Amgen company overviewAmgen annual dividends paid history
| Fiscal year | Period ended | Dividends paid | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.12B | $292.0M | +6.04% |
| 2024 | 2024-12-31 | $4.83B | $276.0M | +6.06% |
| 2023 | 2023-12-31 | $4.56B | $360.0M | +8.58% |
| 2022 | 2022-12-31 | $4.20B | $183.0M | +4.56% |
| 2021 | 2021-12-31 | $4.01B | $258.0M | +6.87% |
| 2020 | 2020-12-31 | $3.75B | $246.0M | +7.01% |
| 2019 | 2019-12-31 | $3.51B | $2.0M | +0.06% |
| 2018 | 2018-12-31 | $3.51B | $142.0M | +4.22% |
| 2017 | 2017-12-31 | $3.37B | $367.0M | +12.24% |
| 2016 | 2016-12-31 | $3.00B | $602.0M | +25.13% |
| 2015 | 2015-12-31 | $2.40B | $545.0M | +29.44% |
| 2014 | 2014-12-31 | $1.85B | $436.0M | +30.81% |
| 2013 | 2013-12-31 | $1.42B | $297.0M | +26.57% |
| 2012 | 2012-12-31 | $1.12B | $618.0M | +123.60% |
| 2011 | 2011-12-31 | $500.0M | $500.0M | — |
| 2010 | 2010-12-31 | $0 | $0 | — |
| 2009 | 2009-12-31 | $0 | — | — |
Amgen quarterly dividends paid
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Dividends paid | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.36B | $82.0M | +6.41% |
| Q1 2026 | 2026-03-31 | $1.36B | $79.0M | +6.18% |
| Q4 2025 | 2025-12-31 | $1.28B | $78.0M | +6.47% |
| Q3 2025 | 2025-09-30 | $1.28B | $72.0M | +5.95% |
| Q2 2025 | 2025-06-30 | $1.28B | $71.0M | +5.87% |
| Q1 2025 | 2025-03-31 | $1.28B | $71.0M | +5.88% |
| Q4 2024 | 2024-12-31 | $1.21B | $65.0M | +5.70% |
| Q3 2024 | 2024-09-30 | $1.21B | $70.0M | +6.14% |
| Q2 2024 | 2024-06-30 | $1.21B | $70.0M | +6.15% |
| Q1 2024 | 2024-03-31 | $1.21B | $71.0M | +6.24% |
| Q4 2023 | 2023-12-31 | $1.14B | $100.0M | +9.62% |
| Q3 2023 | 2023-09-30 | $1.14B | $102.0M | +9.83% |
| Q2 2023 | 2023-06-30 | $1.14B | $101.0M | +9.73% |
| Q1 2023 | 2023-03-31 | $1.14B | $57.0M | +5.28% |
| Q4 2022 | 2022-12-31 | $1.04B | $50.0M | +5.05% |
| Q3 2022 | 2022-09-30 | $1.04B | $39.0M | +3.90% |
| Q2 2022 | 2022-06-30 | $1.04B | $30.0M | +2.98% |
| Q1 2022 | 2022-03-31 | $1.08B | $64.0M | +6.30% |
| Q4 2021 | 2021-12-31 | $990.0M | $58.0M | +6.22% |
| Q3 2021 | 2021-09-30 | $999.0M | $63.0M | +6.73% |
| Q2 2021 | 2021-06-30 | $1.01B | $66.0M | +7.01% |
| Q1 2021 | 2021-03-31 | $1.02B | $71.0M | +7.51% |
| Q4 2020 | 2020-12-31 | $932.0M | $72.0M | +8.37% |
| Q3 2020 | 2020-09-30 | $936.0M | $68.0M | +7.83% |
| Q2 2020 | 2020-06-30 | $942.0M | $62.0M | +7.05% |
| Q1 2020 | 2020-03-31 | $945.0M | $44.0M | +4.88% |
| Q4 2019 | 2019-12-31 | $860.0M | $20.0M | +2.38% |
| Q3 2019 | 2019-09-30 | $868.0M | $17.0M | +2.00% |
| Q2 2019 | 2019-06-30 | $880.0M | $15.0M | +1.73% |
| Q1 2019 | 2019-03-31 | $901.0M | −$50.0M | −5.26% |
| Q4 2018 | 2018-12-31 | $840.0M | $6.0M | +0.72% |
| Q3 2018 | 2018-09-30 | $851.0M | $13.0M | +1.55% |
| Q2 2018 | 2018-06-30 | $865.0M | $19.0M | +2.25% |
| Q1 2018 | 2018-03-31 | $951.0M | $104.0M | +12.28% |
| Q4 2017 | 2017-12-31 | $834.0M | — | — |
| Q3 2017 | 2017-09-30 | $838.0M | $91.0M | +12.18% |
| Q2 2017 | 2017-06-30 | $846.0M | $94.0M | +12.50% |
| Q1 2017 | 2017-03-31 | $847.0M | $95.0M | +12.63% |
| Q3 2016 | 2016-09-30 | $747.0M | $148.0M | +24.71% |
| Q2 2016 | 2016-06-30 | $752.0M | $150.0M | +24.92% |
| Q1 2016 | 2016-03-31 | $752.0M | $153.0M | +25.54% |
| Q4 2015 | 2015-12-31 | $596.0M | — | — |
| Q3 2015 | 2015-09-30 | $599.0M | $135.0M | +29.09% |
| Q2 2015 | 2015-06-30 | $602.0M | $139.0M | +30.02% |
| Q1 2015 | 2015-03-31 | $599.0M | $139.0M | +30.22% |
| Q3 2014 · Sep 30 | 2014-09-30 | $464.0M | $110.0M | +31.07% |
| Q2 2014 | 2014-06-30 | $463.0M | $109.0M | +30.79% |
| Q1 2014 | 2014-03-31 | $460.0M | $107.0M | +30.31% |
| Q3 2013 · Sep 30 | 2013-09-30 | $354.0M | $75.0M | +26.88% |
| Q2 2013 · Jun 30 | 2013-06-30 | $354.0M | $74.0M | +26.43% |
| Q1 2013 · Mar 31 | 2013-03-31 | $353.0M | $68.0M | +23.86% |
| Q3 2012 · Sep 30 | 2012-09-30 | $279.0M | $24.0M | +9.41% |
| Q2 2012 · Jun 30 | 2012-06-30 | $280.0M | $280.0M | — |
| Q1 2012 · Mar 31 | 2012-03-31 | $285.0M | $285.0M | — |
| Q3 2011 | 2011-09-30 | $255.0M | — | — |
| Q2 2011 | 2011-06-30 | $0 | — | — |
| Q1 2011 | 2011-03-31 | $0 | — | — |
Amgen dividends paid trends
Over the last five fiscal years, Amgen's dividends paid increased from $3.75B to $5.12B, a change of $1.37B. The latest reported quarter, Q2 2026, shows $1.36B.
About the metric
What dividends paid mean
Dividends paid are cash distributions made to shareholders. The history shows the company’s aggregate cash outflow for dividends, not the dividend per share, dividend yield, or the date an investor receives a payment.
Calculation and source
Reported cash dividends paid
TickerStat standardizes cash dividends paid to common or ordinary shareholders from official cash-flow filings. Reported zero-dividend periods remain zero and are not treated as missing data. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
